Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Cantor Fitzgerald has maintained its Neutral rating for Regeneron Pharmaceuticals (NASDAQ:REGN) and increased its price target from $800.00 to $850.00. Regeneron's shares are currently trading up 0.63% at $844.91 per share. A move to $850.00 would represent a 0.6% increase from the current share price.
October 16, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained its Neutral rating for Regeneron Pharmaceuticals and raised its price target. This could potentially lead to a slight increase in the stock's price.
The increase in the price target by Cantor Fitzgerald indicates a positive outlook for the company's stock. This could potentially lead to an increase in the stock's price as it signals to investors that the stock is undervalued at its current price. However, the maintained Neutral rating suggests that there are still some uncertainties surrounding the stock's performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100